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ABSTRACT
Previously, we revealed that several kampo medicines used for patients with excess
and/or medium patterns (kakkonto (TJ-1), shosaikoto (TJ-9), hangeshashinto (TJ-14),
and orento (TJ-120)) reduced prostaglandin (PG)E2 levels using LPS-treated human
gingival fibroblasts (HGFs). Recently, we examined other kampo medicines used for
patients with the deficiency pattern [bakumondoto (TJ-29), shinbuto (TJ-30), ninjinto
(TJ-32), and hochuekkito (TJ-41)] and the herbs comprising shinbuto and ninjinto
using the same experimental model. Shinbuto and ninjinto concentration-dependently
reduced LPS-induced PGE2 production byHGFs, whereas hochuekkito weakly reduced
and bakumondoto did not reduce PGE2 production. Shinbuto and ninjinto did not
alter cyclooxygenase (COX) activity or the expression of molecules involved in the
arachidonic acid cascade. Therefore, we next examined which herbs compromising
shinbuto and ninjinto reduce LPS-induced PGE2 production. Among these herbs,
shokyo (Zingiberis Rhizoma) and kankyo (Zingiberis Processum Rhizoma) strongly and
concentration-dependently decreased LPS-induced PGE2 production. However, both
shokyo and kankyo increased the expression of cytosolic phospholipase (cPL)A2 but
did not affect annexin1 or COX-2 expression. These results suggest that shokyo and
kankyo suppress cPLA2 activity. We demonstrated that kampo medicines suppress
inflammatory responses in patients with the deficiency pattern, and in those with excess
or medium patterns. Moreover, kampo medicines that contain shokyo or kankyo are
considered to be effective for the treatment of inflammatory diseases.
Subjects Cell Biology, Dentistry, Pharmacology
Keywords Shokyo, Kankyo, Kampo medicine, Herb, Human gingival fibroblast, Anti-
inflammatory effect, Arachidonic acid cascade, Prostaglandin E2
INTRODUCTION
Periodontal disease is an inflammatory disease of the gingiva that destroys periodontal
tissues. In severe cases, alveolar bone is absorbed. In inflammatory responses and tissue
degradation, prostaglandin E2 (PGE2), interleukin (IL)-6, and IL-8 play important roles.
As PGE2 has several functions in vasodilation, the enhancement of vascular permeability
and pain, and osteoclastogenesis induction, PGE2 participates in inflammatory responses
and alveolar bone resorption in periodontal disease (Noguchi & Ishikawa, 2007).
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Previously, we reported that several kampo medicines, shosaikoto (TJ-9) (Ara et al.,
2008b), orento (TJ-120) (Ara et al., 2010), hangeshashinto (TJ-14) (Nakazono et al., 2010),
and kakkonto (TJ-1) (Kitamura, Urano & Ara, 2014), suppress lipopolysaccharide (LPS)-
induced PGE2 production by human gingival fibroblasts (HGFs). Moreover, we found that
shokyo, kanzo, and keihi, which are herbs contained in kakkonto, reduce PGE2 production
(Ara & Sogawa, 2016). These results suggested that these kampo medicines and herbs have
anti-inflammatory effects in periodontal disease.
However, these kampo medicines are used for patients with the excess pattern or
medium pattern. Kampo medicine used for those with the deficiency pattern remains to be
elucidated. In the present study, we therefore examined the anti-inflammatory effects of the
kampomedicines for patients with the deficiency pattern [bakumondoto (TJ-29), shinbuto
(TJ-30), ninjinto (TJ-32), and hochuekkito (TJ-41)], which are used for the treatment of
inflammatory diseases. Furthermore, we examined the effects on PGE2 production using
herbs comprising the kampo medicines that reduce PGE2 production.
MATERIALS AND METHODS
Reagents
Kampo medicines (bakumondoto, shinbuto, ninjinto, and hochuekkito) were purchased
from Tsumura & Co. (Tokyo, Japan). Powders of 8 herbs (bukuryo, bushi, kankyo, kanzo,
ninjin, shakuyaku, shokyo, and sojutsu) were provided by Tsumura & Co. The ingredients
in shinbuto and ninjinto formulas are shown in Tables 1 and 2. Powders of kampo
medicines or herbs were suspended in Dulbecco’s modified Eagle’s medium (D-MEM;
Sigma, St. Louis, MO, USA) containing 10% heat-inactivated fetal calf serum, 100 units/ml
penicillin, and 100 mg/ml streptomycin (culture medium), and were rotated at 4 ◦C
overnight. Then, the suspensions were centrifuged and the supernatants were filtrated
through a 0.45 µm-pore membrane. Lipopolysaccharide (LPS) from Porphyromonas
gingivalis 381 was provided by Professor Nobuhiro Hanada (School of Dental Medicine,
Tsurumi University, Japan). Arachidonic acid was purchased from Cayman Chemical
(Ann Arbor, MI). Other reagents were purchased from Nacalai tesque (Kyoto, Japan).
Cells
HGFs were prepared as described previously (Nakazono et al., 2010). In brief, HGFs were
prepared from free gingiva during the extraction of an impacted tooth with the informed
consent of the subjects who consulted Matsumoto Dental University Hospital. The free
gingival tissues were cut into pieces and seeded onto 24-well plates (AGC Techno Glass
Co., Chiba, Japan). HGFs were maintained in culture medium at 37 ◦C in a humidified
atmosphere of 5% CO2. For passage, HGFs were trypsinized, suspended, and plated into
new cultures in a 1:3 dilution ratio. HGFs were used between the 10th to 15th passages
in the assays. This study was approved by the Ethical Committee of Matsumoto Dental
University (No. 0063).
Measurement of cell viability
The numbers of cells were measured using WST-8 (Cell Counting Kit-8; Dojindo,
Kumamoto, Japan) according to the manufacturer’s instructions. In brief, the media
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Table 1 The ingredients in the shinbuto formula.
Japanese name Latin name Amount (g) Amount (g/g of product)*
bukuryo Poria Sclerotium 4.0 0.089
shakuyaku Paeoniae Radix 3.0 0.067
sojutsu Atractylodis Lanceae Rhizoma 3.0 0.067
shokyo Zingiberis Rhizoma 1.5 0.033
bushi Processi Aconiti Radix 0.5 0.011
Total 12.0 0.267
Notes.
*7.5 g of shinbuto product contains 2.0 g of a dried extract of the mixed crude drugs.
Table 2 The ingredients in the ninjinto formula.
Japanese name Latin name Amount (g) Amount (g/g of product)*
kankyo Zingiberis Processum Rhizoma 3.0 0.083
kanzo Glycyrrhizae Radix 3.0 0.083
sojutsu Atractylodis Lanceae Rhizoma 3.0 0.083
ninjin Ginseng Radix 3.0 0.083
Total 12.0 0.333
Notes.
*7.5 g of ninjinto product contains 2.5 g of a dried extract of the mixed crude drugs.
were removed by aspiration and the cells were treated with a 100-µl mixture of WST-8
with culture medium for 2 h at 37 ◦C in CO2 incubator. Optical density was measured
(measured wavelength at 450 nm and reference wavelength at 655 nm) using an iMark
microplate reader (Bio-Rad, Hercules, CA, USA), and the mean background value was
subtracted from each value. Data is represented as means ± S.D. (n= 4).
Measurement of prostaglandin E2 (PGE2), interleukin (IL)-6, and IL-8
HGFs were seeded in 96-well plates (10,000 cells/well) and incubated in serum-containing
medium at 37 ◦C overnight. Then, the cells were treated with varying concentrations of
each kampo medicine (0, 0.01, 0.1, or 1 mg/ml) or each herb (0, 10, 30, or 100 µg/ml)
in the absence or presence of LPS (10 ng/ml) for 24 h (200 µl per well) in triplicate or
quadruplicate for each sample. After the culture supernatants were collected, viable cell
numbers were measured using WST-8 as described above.
The concentrations of PGE2, IL-6, and IL-8 in the culture supernatants weremeasured by
enzyme-linked immunosorbent assay (ELISA) according to themanufacturer’s instructions
(PGE2), Cayman Chemical; IL-6 and IL-8, Thermo Fisher Scientific Inc., Camarillo, MA,
USA), and were adjusted by the number of viable cells. Data are represented as pg or ng
per 10,000 cells (mean ± S.D.).
Measurement of cyclooxygenase (COX)-2 activity
COX-2 activity was evaluated as reported previously (Wilborn et al., 1995) with slight
modification. In brief, to estimate COX-2 activity, HGFs were treated with LPS and herbs
for 8 h, washed, and incubated in culture medium containing exogenous arachidonic acid
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(10 µM). The concentrations of PGE2 in the supernatants were measured by ELISA. Data
are represented as pg per 10,000 cells (mean ± S.D.).
Preparation of cell lysates
HGFs were cultured in 60-mm dishes and treated with combinations of LPS and herbs for
the indicated times. Then, cells were washed twice with Tris-buffered saline, transferred
into microcentrifuge tubes, and centrifuged at 6,000 × g for 5 min at 4 ◦C. Supernatants
were aspirated and cells were lysed on ice in lysis buffer (50 mM Tris–HCl, pH 7.4, 1%
Nonidet P-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM ethyleneglycol bis(2-
aminoethylether)tetraacetic acid (EGTA), 1 mM sodium orthovanadate, 10 mM sodium
fluoride, 1/100 volume of protease inhibitor cocktail (Nacalai tesque)) for 30 min at 4 ◦C.
Samples were next centrifuged at 12,000 × g for 15 min at 4 ◦C, and supernatants were
collected. The protein concentration was measured using a BCA Protein Assay Reagent kit
(Pierce Chemical Co., Rockford, IL, USA).
Western blotting
The samples (10 µg of protein) were fractionated in a polyacrylamide gel under reducing
conditions and transferred onto a polyvinylidene difluoride (PVDF) membrane (Hybond-
P; GE Healthcare, Uppsala, Sweden). The membranes were blocked with 5% ovalbumin
for 1 h at room temperature and incubated with primary antibody for an additional 1 h.
Themembranes were further incubated with horseradish peroxidase-conjugated secondary
antibodies for 1 h at room temperature. Protein bands were visualized with an ECL kit (GE
Healthcare). Densitometric values of each band were calculated using ImageJ software.
Antibodies against COX-2 (sc-1745, 1:500 dilution), cytosolic PLA2 (cPLA2) (sc-
438, 1:200 dilution), annexin1 (sc-11387, 1:1,000 dilution), and actin (sc-1616, 1:1,000
dilution), which detects a broad range of actin isoforms, were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). Antibodies against extracellular signal-regulated
kinase (ERK; p44/42 MAP kinase antibody, 1:1,000 dilution) and phosphorylated ERK
[Phospho-p44/42 MAPK (Thr202/Tyr204) (E10) monoclonal antibody, 1:2,000 dilution]
were from Cell Signaling Technology (Danvers, MA). Horseradish peroxidase-conjugated
anti-goat IgG (sc-2020, 1:20,000 dilution) was from Santa Cruz, and anti-rabbit IgG
(1:20,000 dilution) and anti-mouse IgG (1:20,000 dilution) were from DakoCytomation
(Glostrup, Denmark).
Statistical analysis
Differences between groups were evaluated by the two-tailed pairwise comparison test with
a pooled variance, followed by correction with the Holmmethod (total 10 null hypotheses;
five null hypotheses without kampo vs. with kampo in the absence or presence of LPS in
Fig. 1, total 10 null hypotheses; three null hypotheses without kampo vs. with kampo in
the absence of LPS, three null hypotheses without kampo vs. with kampo in the presence
of LPS, and four null hypotheses without LPS vs. with LPS in Fig. 2). Differences between
the control group and experimental groups were evaluated by a two-tailed Dunnett’s test.
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Figure 1 Effects of kampomedicines on cytotoxicity.HGFs were treated with combinations of LPS (0
or 10 ng/ml) and kampo medicine (0, 0.5, 1, 2, 5, or 10 mg/ml) for 24 h. Then, the numbers of viable cells
were measured with WST-8. Open circles, treatment without LPS; closed circles, treatment with 10 ng/ml
of LPS. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 (without vs. with kampo medicine). P values were calculated
by pairwise comparisons and corrected with the Holm method (10 null hypotheses).
Full-size DOI: 10.7717/peerj.4120/fig-1
All computations were performed with the statistical program R (R Core Team, 2017).
Dunnett’s test was performed using the ‘glht’ function in the ‘multcomp’ package. Values
with P < 0.05 were considered significantly different.
RESULTS
Effects of kampo medicines on HGFs viability
First, we examined the effects of four kampomedicines (bakumondoto, shinbuto, ninjinto,
and hochuekkito) on HGFs viability. Bakumondoto did not affect the viability up to 10
mg/ml at 24 h treatment (Fig. 1A). In contrast, Shinbuto, ninjinto, and hochuekkito did not
affect the viability up to 2 mg/ml, but decreased at 5 mg/ml and 10 mg/ml (Figs. 1B–1C).
Therefore, up to 1 mg/ml of kampo medicines was used in further experiments because
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Figure 2 Effects of kampomedicines on PGE2, IL-6, and IL-8 production. HGFs were treated with
combinations of LPS (0 or 10 ng/ml) and kampo medicine (0, 0.01, 0.1, or 1 mg/ml) for 24 h. Concentra-
tions of PGE2 (A–D), IL-6 (E–H), and IL-8 (I–L) were measured by ELISA, adjusted by cell number, and
expressed as per 10,000 cells (mean± S.D., n = 3). Open circles, treatment without LPS; closed circles,
treatment with 10 ng/ml of LPS. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 (without vs. with kampo medicine).
#P < 0.05, ##P < 0.01, ###P < 0.001 (without LPS vs. with LPS). P values were calculated by pairwise com-
parisons and corrected with the Holm method (10 null hypotheses).
Full-size DOI: 10.7717/peerj.4120/fig-2
we used the same concentration of kampo medicines in previous studies (Ara et al., 2008b;
Ara et al., 2010; Nakazono et al., 2010; Kitamura, Urano & Ara, 2014).
Effects of kampo medicines on prostaglandin (PG)E2, interleukin
(IL)-6, and IL-8 production
We examined whether these kampo medicines affected the production of PGE2 and
inflammatory cytokines (IL-6 and IL-8) by HGFs. The concentrations of PGE2, IL-6,
and IL-8 were adjusted according to viable cell number. HGFs treated with 10 ng/ml of
LPS produced large amounts of PGE2, IL-6, and IL-8. Shinbuto and ninjinto strongly
and concentration-dependently reduced LPS-induced PGE2 production (Figs. 2B–2C).
In contrast, bakumondoto and hochuekkito had no or little effect on PGE2 production.






















Figure 3 Effects of kampomedicines on COX activity.HGFs were treated with LPS (10 ng/ml) and
kampo medicine (1 mg/ml) for 8 h, washed, and then treated with 10 µM arachidonic acid for 30 min.
Concentrations of PGE2 were measured by ELISA, adjusted by cell number, and expressed as per 10,000
cells (mean± S.D., n= 4). P values by Dunnett’s test are indicated.
Full-size DOI: 10.7717/peerj.4120/fig-3
Bakumondoto weakly, and shinbuto, ninjinto, and hochuekkito strongly increased LPS-
induced IL-6 production (Figs. 2E–2H). Bakumondoto and hochuekkito weakly increased
LPS-induced IL-8 production, but shinbuto and ninjinto did not affect IL-8 production
(Figs. 2I–2L).
From these results, we selected two kampo medicines, shinbuto and ninjinto, which
decreased PGE2 production and used them in the following experiments.
Effects of shinbuto and ninjinto on the arachidonic acid cascade
To clarify the mechanism of how shinbuto and ninjinto reduced LPS-induced PGE2
production more directly, we examined the effects of these two kampo medicines on the
arachidonic acid cascade. First, we examined the effects of shinbuto and ninjinto on COX
activity. In order to bypass PLA2, we added exogenous arachidonic acid to HGFs treated
with LPS alone or LPS plus kampomedicine (shinbuto or ninjinto). Then, wemeasured the
PGE2 level produced by COX. However, shinbuto and ninjinto did not affect LPS-induced
PGE2 production (Fig. 3).
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Figure 4 Effects of kampomedicines on cPLA2, annexin1, and COX-2 expression. HGFs were treated
with a combination of LPS (0 or 10 ng/ml) and kampo medicines (0 or 1 mg/ml) for 8 h, and protein lev-
els were examined by Western blotting. The band densities were normalized against LPS alone and actin,
and indicated below each band. shi, shinbuto; ni, ninjinto.
Full-size DOI: 10.7717/peerj.4120/fig-4
Next, we examinedwhether shinbuto and ninjinto affected the expression ofmolecules in
the arachidonic acid cascade. cPLA2, which is the most upstream enzyme in the arachidonic
acid cascade, releases arachidonic acid from plasma membranes. Shinbuto slightly reduced
cPLA2 expression and ninjinto slightly increased cPLA2 expression (Fig. 4A). COX-2
was weakly expressed in the absence of LPS, and the treatment with LPS alone increased
COX-2 expression. However, shokyo did not alter but kankyo slightly increased LPS-
induced COX-2 expression (Fig. 4). Annexin1 (also named lipocortin1) is produced
by glucocorticoids and inhibits cPLA2 activity (Gupta et al., 1984; Wallner et al., 1986).
Shinbuto and ninjinto slightly increased annexin1 expression (Fig. 4A) in a concentration-
dependent manner (Fig. 4B).
Lastly, we evaluated the effects of shinbuto and ninjinto on ERK phosphorylation. cPLA2
is directly phosphorylated and activated by phosphorylated ERK (Lin et al., 1993; Gijón et
al., 1999). Therefore, we examined whether shinbuto and ninjinto suppressed LPS-induced
ERK phosphorylation. LPS treatment enhanced ERK phosphorylation at 0.5 h and its
phosphorylation was attenuated. However, 1 mg/ml of shinbuto or ninjinto did not affect
LPS-induced ERK phosphorylation (Fig. 5).
Effects of herbs on PGE2 production and molecular expression in the
arachidonic acid cascade
We examined whether herbs which comprising shinbuto and ninjinto affected LPS-induced
PGE2, IL-6 and IL-8 production by HGFs. When HGFs cells were treated with 10 ng/ml of
LPS, HGFs cells produced large amounts of PGE2. Bukuryo increased LPS-induced PGE2
production. Shokyo, kankyo and kanzo strongly and significantly reduced LPS-induced
PGE2 production (Fig. 6A). Moreover, shokyo and kankyo decreased PGE2 production in
a concentration-dependent manner (Figs. 6D–6E). Other herbs had little or no effect on
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Figure 5 Effects of kampomedicines on LPS-induced ERK phosphorylation.HGFs were untreated (0
h), treated with LPS (10 ng/ml), or treated with both LPS and kampo medicines (1 mg/ml) for 0.5, 1, or 2
h. PMA was used as a positive control. Western blotting was performed using anti-phosphorylated ERK
or anti-ERK antibodies. pERK, phosphorylated ERK. The upper band indicates ERK1 (p44 MAPK) and
lower band ERK2 (p42 MAPK).
Full-size DOI: 10.7717/peerj.4120/fig-5
PGE2 production. Bukuryo increased LPS-induced IL-6 and IL-8 production, and kankyo
increased IL-8 production (Figs. 6B–6C). Kanzo reduced IL-6 production (Fig. 6B).
We then examined whether shokyo and kankyo affected the expression of molecules in
the arachidonic acid cascade. Both shokyo and kankyo increased the expression of cPLA2
but did not affect annexin1 or COX-2 expression (Fig. 7).
DISCUSSION
In our previous studies, we reported the importance of HGFs in the study of periodontal
disease (Kamemoto et al., 2009; Ara et al., 2010; Nakazono et al., 2010; Ara et al., 2012;
Kitamura, Urano & Ara, 2014;Ara & Sogawa, 2016), becauseHGFs are themost prominent
cells in periodontal tissue. Moreover, LPS-treated HGFs produce inflammatory chemical
mediators, such as PGE2 and inflammatory cytokines such as IL-6 and IL-8 (Sismey-Durrant
& Hopps, 1991; Bartold & Haynes, 1991; Tamura et al., 1992). Moreover, HGFs continue to
produce PGE2 (Ara et al., 2008a), IL-6, and IL-8 (Ara et al., 2009) in the presence of LPS.

































































































































































































Figure 6 Effects of herbs on LPS-induced PGE2, IL-6, and IL-8 production. (A–C) HGFs were treated
with combinations of LPS (0 or 10 ng/ml) and each herb (100 µg/ml) for 24 h. Concentrations of PGE2
(A), IL-6 (B), and IL-8 (C) were measured by ELISA, adjusted by cell number, and expressed as per 10,000
cells (mean± S.D., n = 3). (D–E) HGFs were treated with combinations of LPS (10 ng/ml) and herbs (0,
1, 10, or 100 µg/ml) for 24 h. Concentrations of PGE2 were measured by ELISA, adjusted by cell number,
and expressed as per 10,000 cells (mean± S.D., n= 3). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 (LPS alone vs.
LPS plus herb, Dunnett’s test).
Full-size DOI: 10.7717/peerj.4120/fig-6
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Figure 7 Effects of shokyo and kankyo on cPLA2, annexin1, and COX-2 expression. HGFs were treated
with a combination of LPS (0 or 10 ng/ml) and herbs (1 mg/ml) for 8 h, and protein levels were examined
by Western blotting. The band densities were normalized against LPS alone and actin, and indicated below
each band. s, shokyo; k, kankyo.
Full-size DOI: 10.7717/peerj.4120/fig-7
Therefore, the large amount of chemical mediators and cytokines derived from HGFs may
be contained in periodontal tissues. From these findings, we believe that examining the
effects of drugs on HGFs is needed in the study of periodontal disease.
In the present study, we examined the effects of kampomedicines on LPS-induced PGE2,
IL-6, and IL-8 production by HGFs in patients with the deficiency pattern. Shinbuto and
ninjinto dose-dependently reduceed LPS-induced PGE2 production (Figs. 2B–2C), similar
with shosaikoto, hangeshashinto, orento, and kakkonto (Ara et al., 2008b; Nakazono et
al., 2010; Ara et al., 2010; Kitamura, Urano & Ara, 2014). However, shinbuto and ninjinto
increased LPS-induced IL-6 and IL-8 production (Figs. 2F–2G, 2J–2K). In general, acid
non-steroidal anti-inflammatory drugs (NSAIDs) exhibit anti-inflammatory effects by
suppressing PGE2 production even though they do not affect IL-6 or IL-8 production.
Therefore, our results suggest that shinbuto and ninjinto have anti-inflammatory effects in
periodontal disease similar with acid NSAIDs.
In the experiments at the herb level, shokyo (Zingiberis Rhizoma), kankyo (Zingiberis
Processum Rhizoma), and kanzo (Glycyrrhizae Radix) reduced PGE2 production (Fig. 6).
Shokyo is contained in shinbuto (Table 1), and kankyo and kanzo are contained in ninjinto
(Table 2). Shokyo is the powdered rhizome of ginger (Zingiber offinale Roscoe), whereas,
kankyo is the steamed and powdered rhizome of ginger. Many reports demonstrated
Ara and Sogawa (2017), PeerJ, DOI 10.7717/peerj.4120 11/17
that ginger has anti-inflammatory effects in human (Afzal et al., 2001; Lakhan, Ford &
Tepper, 2015), animal (Thomson et al., 2002; Aimbire et al., 2007; El-Abhar, Hammad &
Gawad, 2008), and in vitro models (Ara & Sogawa, 2016; Podlogar & Verspohl, 2012).
Shokyo contains gingerols such as 6-, 8-, and 10-gingerols. With prolonged storage or
heat-treatment of ginger, gingerols are converted to shogaols, which are the dehydrated
form of the gingerols (Afzal et al., 2001). Therefore, kankyo contains the largest amount of
shogaols.
Recently, we found that shokyo suppressed LPS-induced PGE2 production by HGFs and
that shokyo may suppress PLA2 activity (Ara & Sogawa, 2016). In the present study, we
examined the effects of kankyo in comparison with shokyo. Shokyo and kankyo increased
cPLA2 expression but did not alter annexin1 expression (Fig. 7). Moreover, we revealed
that shinbuto and ninjinto, which contain shokyo and kankyo respectively, did not alter
PGE2 production when arachidonic acid was added to bypass the upstream pathway
(Fig. 3). These data suggest that shokyo and kankyo did not affect the downstream pathway
of arachidonic acid, which includes COX-2 and PGE synthase. In addition, shinbuto
and ninjinto did not affect ERK phosphorylation (Fig. 5). From our findings described
above, we were unable to explain the mechanism of the reduction in PGE2 production.
As gingerols in ginger are reported to inhibit both calcium-independent PLA2 (iPLA2)
and cPLA2 activities (Nievergelt et al., 2011), shokyo and kankyo are suggested to inhibit
PLA2 as discussed in the previous study (Ara & Sogawa, 2016). Previously, we reported
that cPLA2 is the main isoform in HGFs (Ara & Sogawa, 2016) among the subtypes such
as cPLA2, iPLA2, and secretory PLA2 (sPLA2) (Burke & Dennis, 2009). Therefore, shokyo
and kankyo may mainly inhibit cPLA2 activity in HGFs. We found that orento decreases
LPS-induced PGE2 production via the suppression of ERK phosphorylation (Ara et al.,
2010). However, orento may also reduce LPS-induced PGE2 production by inhibition of
cPLA2 activity because orento contains kankyo.
We demonstrated that shokyo and kankyo concentration-dependently reduced LPS-
induced PGE2 production (Fig. 6A), and that the effects of kankyo are slightly stronger
than those of shokyo (Figs. 6D–6E). In previous study, 6- and 8-gingerols were found to
not inhibit cPLA2 activity, but 10-gingerol and 6-, 8-, and 10-shogaols did (Nievergelt et
al., 2011). Therefore, the difference in these effects on PGE2 production between shokyo
and kankyo may be due to the amount of shogaols in these herbs.
We demonstrated that shinbuto and ninjinto slightly increased annexin1 expression
(Fig. 4). However, the involvement of annexin1 in the reduction in PGE2 production is
unlikely. Shokyo and kankyo did not alter annexin1 expression (Fig. 7). All 4 herbs other
than shokyo in shinbuto did not reduce PGE2 production, but rather, bukuryo increased
PGE2 production (Fig. 6A). Similarly, kanzo in ninjinto increased annexin1 expression in
HGFs, and kanzo also inhibited COX activity (Ara & Sogawa, 2016). The 2 residual herbs
other than kankyo and kanzo did not reduce PGE2 production (Fig. 6A). Therefore, the
increased annexin1 expression did not contribute to decreased PGE2 production.
At the herb level, we were unable to clarify which herbs affect cytokine production.
Bukuryo in shinbuto increased LPS-induced IL-6 and IL-8 production (Figs. 6B–6C).
Therefore, this effect of shinbuto on increased IL-6 production may be due to bukuryo.
Ara and Sogawa (2017), PeerJ, DOI 10.7717/peerj.4120 12/17
However, shinbuto did not alter IL-8 production even though it contains bukuryo.
Moreover, although ninjinto increased LPS-induced IL-6 production, kanzo reduced IL-6
production, and the other three herbs, kankyo, sojutsu, and ninjin, did not alter IL-6
production. Similarly, although ninjinto did not alter IL-8 production, kankyo increased
IL-8 production. Therefore, the effects of herbs on IL-6 and IL-8 production are considered
to not be due to a single herb but to the combination of herbs.
Both the expression of COX-2, and the production of IL-6 and IL-8 are widely known to
be regulated byNF-κB. Ginger and its components gingerol and shogaol have been reported
to suppress NF-κB activation, and to reduce COX-2 expression and the production of IL-6
and IL-8. For example, ginger suppressed NF-κB activation in ovarian cancer cells (Rhode
et al., 2007), and 6-gingerol suppressed NF-κB activation inmouse macrophage RAW264.7
cells (Pan et al., 2008), TPA-treated mouse skin in vivo (Kim et al., 2005), and in intestinal
epithelial cells (Saha et al., 2016). Similarly, 6-shogaol suppressed NF-κB activation in
mouse macrophage RAW264.7 cells (Pan et al., 2008) and microglia cells (Ha et al., 2012).
6-Gingerol and 6-shogaol suppressed COX-2 expression in mouse macrophage RAW264.7
cells (Pan et al., 2008) and primary rat astrocytes (Shim et al., 2011). 6-Gingerol reduced
the production of IL-1α, IL-1β, IL-6, and IL-8 in intestinal epithelial cells (Saha et al.,
2016). However, shinbuto and ninjinto, which contain shokyo and kankyo, respectively,
increased LPS-induced IL-6 and IL-8 production by HGFs (Fig. 2) similar with kakkonto
(Kitamura, Urano & Ara, 2014). Moreover, these two kampo medicines, shokyo, and
kankyo did not suppress COX-2 expression (Figs. 4A and 7). These findings raised the
possibility that shokyo and kankyo, their components, gingerols and shogaols, do not
suppress the NF-κB pathway in HGFs. The assumption is able to explain why shokyo and
kankyo did not suppress COX-2 expression, which is also regulated by the NF-κB pathway.
Furthermore, 6-gingerol and 6-shogaol had no effect on LPS-induced IL-8 production
in human bronchial epithelial cells (Podlogar & Verspohl, 2012). Therefore, the effects of
gingerols and shogaols may be different among cell types.
CONCLUSION
We demonstrated that shinbuto and ninjinto reduced LPS-induced PGE2 production
by HGFs. Moreover, shokyo and kankyo, which are included in these kampo medicines
respectively, concentration-dependently reduced LPS-induced PGE2 production. However,
shokyo and kankyo did not alter the expression of the molecules in the arachidonic acid
cascade, suggesting that shokyo and kankyo inhibit cPLA2 activity. Therefore, the kampo
medicines that contain shokyo or kankyo may have the ability to reduce PGE2 production.
We found that the kampo medicines used for patients with the deficiency pattern also have
anti-inflammatory effects in those with the excess pattern or medium pattern. We expect
kampo medicines to be used for improving inflammatory diseases, such as periodontal
disease and stomatitis, in patients with any pattern.
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